Pinco Biotherapeutics Announces Strategic Investment from Advisor Anton Dormer, MD, MS
Investment Supports Advancement of DNA Plasmid–Based Therapy for Neuropathic Pain
Silver Spring, MD – February 19, 2026 — Pinco Biotherapeutics, a preclinical biotherapeutic company developing a novel DNA plasmid–based therapy for neuropathic pain, today announced a strategic investment from Anton Dormer, MD, MS, a physician, biotech entrepreneur, and advisor to the company. The amount of the investment was not disclosed.
Neuropathic pain affects more than 820 million people globally, resulting in billions of dollars in healthcare costs annually. Current treatments largely focus on symptom management, leaving patients without a long-term, root-cause solution. PincoBio is revolutionizing this space by targeting the Nav1.7 ion channel, a well-established molecular gatekeeper in pain signaling, using a proprietary DNA plasmid-based drug platform that offers longer-lasting, reversible, and tunable therapeutic effects.
“Anton’s investment is a strong vote of confidence in both our scientific strategy and our long-term vision,” said Scott Alpizar, PhD, CEO of Pinco Biotherapeutics. “As a physician and experienced biotech founder, Anton brings a translational lens that aligns closely with our goal of developing a durable, non-addictive therapy that meaningfully improves outcomes for patients with chronic neuropathic pain.”
Dr. Dormer serves as an advisor to Pinco Biotherapeutics and is a co-inventor of the technology that underpins key aspects of the company’s scientific strategy. His background spans medicine, research, and company building, with experience advancing therapeutics from early concept through translational development. He is also the CEO of BioLabShare, Inc., a mission-driven life sciences incubator focused on expanding access to affordable wet lab and office space for biotech, life sciences, and health AI entrepreneurs
“Pinco is tackling one of the most challenging and underserved areas in medicine,” said Dr. Dormer. “Their DNA plasmid-based approach to modulating Nav1.7 is scientifically compelling and thoughtfully engineered for specificity, durability, and safety. I believe this platform has the potential to redefine how we treat neuropathic pain - and believe this team has the discipline and technical depth to execute.”
Pinco Biotherapeutics’ leadership team also includes Daniel Achinko, PhD (Chief Scientific Officer), Elton Norman, Esq., CPA (Chief Financial Officer), and additional advisors Mahesh Narayanan, MS, Swami Nathan, and Mason Diamond, alongside Dr. Dormer. The company is currently advancing in-vitro proof-of-concept studies and plasmid optimization, with plans to initiate in-vivo efficacy and safety studies as part of its preclinical development program.
About Pinco Biotherapeutics
Pinco Biotherapeutics is a preclinical therapeutics company developing non-viral DNA plasmid–based drugs for chronic neuropathic pain. By directly targeting validated molecular drivers of pain, Pinco’s plasmid is designed to deliver durable, non-addictive relief while avoiding the systemic side effects of small molecules and the immunogenicity risks of viral gene therapies.
